Pfizer's Bondholders Cheer News of Activist Investor Starboard's $1 Billion Investment

MarketWatch34minutes ago

RSV vaccine sales plummet in the United States, as the 'most imaginative product' faces a heavy blow from the CDC.

①Independent pharmacists have reported that the demand for RSV vaccines in autumn has decreased by two-thirds compared to a year ago; ②In September last year, an average of about 0.44 million people per week received the glaxosmithkline or pfizer RSV vaccine; whereas this September, the average weekly number is around 0.157 million people.

cls.cnOct 8 10:32 ET

Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help. -- WSJ

WSJOct 8 09:00 ET

Daily short sale tracking: NVIDIA's short volume increased by 7 million, with a short sale ratio of 8%

Moomoo NewsOct 8 09:00 ET

GSK Arexvy Protects From RSV Over Three Full Seasons

Seeking AlphaOct 8 08:32 ET

glaxosmithkline (GSK.US) claimed that the protection of the RSV vaccine can last for three quarters.

glaxosmithkline (GSK.US) stated on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.

Zhitong FinanceOct 8 08:25 ET